Updated norovirus outbreak management and disease prevention guidelines by Gregoricus, Nicole et al.
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
Morbidity and Mortality Weekly Report
Recommendations and Reports / Vol. 60 / No. 3 March 4, 2011 
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Updated Norovirus Outbreak Management 
and Disease Prevention Guidelines
Recommendations and Reports
The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), 
U.S. Department of Health and Human Services, Atlanta, GA 30333.
Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR 2011;60(No. RR-#):[inclusive page numbers].
Centers for Disease Control and Prevention
Thomas R. Frieden, MD, MPH, Director
Harold W. Jaffe, MD, MA, Associate Director for Science
James W. Stephens, PhD, Office of the Associate Director for Science
Stephen B. Thacker, MD, MSc, Deputy Director for Surveillance, Epidemiology, and Laboratory Services
Stephanie Zaza, MD, MPH, Director, Epidemiology and Analysis Program Office
MMWR Editorial and Production Staff
Ronald L. Moolenaar, MD, MPH, Editor, MMWR Series
Christine G. Casey, MD, Deputy Editor, MMWR Series
Teresa F. Rutledge, Managing Editor, MMWR Series
David C. Johnson, Lead Technical Writer-Editor
Jeffrey D. Sokolow, MA, Project Editor
Martha F. Boyd, Lead Visual Information Specialist
Malbea A. LaPete, Julia C. Martinroe,
Stephen R. Spriggs, Terraye M. Starr
Visual Information Specialists
Quang M. Doan, MBA, Phyllis H. King
Information Technology Specialists
MMWR Editorial Board
William L. Roper, MD, MPH, Chapel Hill, NC, Chairman
Virginia A. Caine, MD, Indianapolis, IN
Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA
David W. Fleming, MD, Seattle, WA
William E. Halperin, MD, DrPH, MPH, Newark, NJ
King K. Holmes, MD, PhD, Seattle, WA
Deborah Holtzman, PhD, Atlanta, GA
John K. Iglehart, Bethesda, MD
Dennis G. Maki, MD, Madison, WI
Patricia Quinlisk, MD, MPH, Des Moines, IA
Patrick L. Remington, MD, MPH, Madison, WI
Barbara K. Rimer, DrPH, Chapel Hill, NC
John V. Rullan, MD, MPH, San Juan, PR
William Schaffner, MD, Nashville, TN
Anne Schuchat, MD, Atlanta, GA
Dixie E. Snider, MD, MPH, Atlanta, GA












Real-Time RT-PCR Assays .................................................................................7





Prevention and Control .......................................................................................9
Hand Hygiene .....................................................................................................9
Exclusion and Isolation ................................................................................. 10
Environmental Disinfection ........................................................................ 10
Reporting and Assistance ................................................................................ 11
National Outbreak Reporting System ..................................................... 11
CaliciNet ............................................................................................................. 11
References ............................................................................................................. 12
On the cover: Transmission electron micrograph of norovirus particles (Courtesy: Charles D. Humphrey, PhD, CDC).
Recommendations and Reports
MMWR / March 4, 2011 / Vol. 60 / No. 3 1
Introduction
The prototype norovirus was first identified as the cause 
of a gastroenteritis outbreak in Norwalk, Ohio, in 1968 (1). 
However, the epidemiology of noroviruses remained poorly 
characterized until relatively recently because of the lack 
of widespread availability of sensitive diagnostic methods. 
Electron microscopy was the first tool used for identifying 
noroviruses but proved to be a time-consuming and insensi-
tive method that was rarely available outside of research set-
tings. Immunologic assays developed during the late 1970s 
and 1980s improved detection rates (2) but lacked broad 
reactivity to detect the full spectrum of noroviruses and were 
not widely available, limiting their utility for routine use 
in outbreak investigations. Consequently, the cause of the 
majority of gastroenteritis outbreaks could not be determined. 
Because of these limitations of laboratory diagnostics, clinical 
and epidemiologic criteria were developed to help attribute 
gastroenteritis outbreaks to norovirus (3). These criteria have 
subsequently been validated as highly sensitive (99%) and 
moderately specific (68%) (4). Since the 1990s, the develop-
ment and subsequent widespread use of molecular diagnostic 
assays have led to substantial improvements in understanding 
the role of noroviruses in gastroenteritis outbreaks (5), par-
ticularly among those involving foodborne transmission and 
those occurring in long-term–care facilities (6,7). Nonetheless, 
progress in the characterization and control of norovirus has 
been hampered by the lack of a rapid and sensitive assay for 
use in clinical settings and the inability to cultivate human 
noroviruses in cell culture.
Since 2001, when CDC published the most recent norovirus 
recommendations (8), substantial advances have been made 
in norovirus epidemiology, immunology, diagnostic methods, 
and infection control. This report reviews these advances and 
provides guidelines for outbreak management and disease 
prevention. Specific recommendations include standardized 
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Summary
Noroviruses are the most common cause of epidemic gastroenteritis, responsible for at least 50% of all gastroenteritis outbreaks 
worldwide, and a major cause of foodborne illness. In the United States, approximately 21 million illnesses attributable to norovirus 
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Although the inability to culture human noroviruses in vitro has hampered progress, assessment of the performance of disinfectants 
has been facilitated by the discovery of new, cultivable surrogates for human noroviruses. In addition, the periodic emergence 
of epidemic strains (from genogroup II type 4, GII.4) and outbreaks in specific populations (e.g., the elderly in nursing homes) 
have been characterized. This report reviews these recent advances and provides guidelines for outbreak management and disease 
prevention. These recommendations are intended for use by public health professionals investigating outbreaks of acute gastroenteritis, 
including state and local health authorities, as well as academic and research institutions.
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collection of clinical specimens during norovirus outbreaks, 
use of two recently launched surveillance systems for reporting 
of norovirus outbreaks, and use of appropriate control mea-
sures focusing on hand hygiene, environmental disinfection, 
and exclusion of ill persons (Box). Their implementation by 
public health professionals is intended to guide efficient use 
of public health resources for effective prevention and control 
of norovirus disease.
Methods
These guidelines were developed by CDC subject matter 
experts based on a critical review of published literature and 
unpublished data from outbreak investigations. In June 2010, 
a preliminary version of these guidelines was presented at 
the Council of State and Territorial Epidemiologists annual 
conference to solicit input from state and local public health 
partners. A draft report was subsequently shared for comment 
with representatives from five state or local health departments 
and the U.S. Food and Drug Administration (FDA). These 
recommendations complement the CDC Healthcare Infection 
Control Practices Advisory Committee (HICPAC) guideline 
for the prevention and control of norovirus gastroenteritis out-
breaks in health-care settings (9), the model FDA Food Code 
for retail food and institutional foodservice settings (10), and 
other applicable state or local regulatory guidance, by providing 
general principles advisable across all outbreak settings.
Biology and Epidemiology
The Virus
Noroviruses are a group of nonenveloped, single-stranded 
RNA viruses classified into the genus Norovirus (previously 
referred to as Norwalk-like viruses [NLVs] or small round-
structured viruses [SRSVs]) of the family Caliciviridae. Other 
genera within the Caliciviridae family include Sapovirus 
(previously referred to as Sapporo-like viruses [SLVs]), which 
also cause acute gastroenteritis (AGE) in persons, as well as 
Lagovirus, Vesivirus, and Nebovirus, which are not pathogenic 
BOX. Key points for investigation and response to norovirus outbreaks
•	 Initiate	investigations	promptly,	including	collection	of	
clinical and epidemiologic information, to help iden-
tify predominant mode of transmission and possible 
source.
•	 Promote	good	hand	hygiene,	including	frequent	wash-
ing with soap and running water for a minimum of 
20 seconds. If available, alcohol-based hand sanitizers 
(≥70% ethanol) can be used as an adjunct in between 
proper handwashings but should not be considered a 
substitute for soap and water handwashing.
•	 Exclude	ill	staff	in	certain	positions	(e.g.,	food,	child-
care, and patient-care workers) until 48–72 hours after 
symptom resolution. In closed or institutional settings 
(e.g., long-term–care facilities, hospitals, and cruise 
ships), isolate ill residents, patients, and passengers 
until 24–48 hours after symptom resolution. In licensed 
food establishments, approval from the local regulatory 
authority might be necessary before reinstating a food 
employee following a required exclusion.
•	 Reinforce	 effective	 preventive	 controls	 and	 employee	
practices (e.g., elimination of bare-hand contact with 
ready-to-eat foods and proper cleaning and sanitizing 
of equipment and surfaces).
•	 After	initial	cleaning	to	remove	soiling,	disinfect	poten-
tially contaminated environmental surfaces using a 
chlorine bleach solution with a concentration of 1,000–
5,000 ppm (1:50–1:10 dilution of household bleach 
[5.25%]) or other Environmental Protection Agency 
(EPA)–approved disinfectant.* In health-care settings, 
cleaning products and disinfectants used should be EPA-
registered and have label claims for use in health care; 
personnel performing environmental services should 
adhere to the manufacturer’s instructions for dilution, 
application, and contact time.
•	 Collect	whole	 stool	 specimens	 from	at	 least	 five	per-
sons during the acute phase of illness (≤72 hours from 
onset) for diagnosis by TaqMan-based real-time reverse 
transcription-PCR (RT-qPCR), perform genotyping on 
norovirus-positive stool specimens, and report results 
to CDC via CaliciNet (CDC’s electronic norovirus 
outbreak surveillance network ).
•	 Report	 all	 outbreaks	 of	 acute	 gastroenteritis	 to	 state	
and local health departments, in accordance with local 
regulations, and to CDC via the National Outbreak 
Reporting System (NORS).
* Agents registered as effective against norovirus by EPA are available at http://www.epa.gov/oppad001/list_g_norovirus.pdf. Evidence for efficacy against norovirus 
usually is based on studies using feline calicivirus (FCV) as a surrogate. However, FCV and norovirus exhibit different physiochemical properties, and whether 
inactivation of FCV reflects efficacy against norovirus is unclear.
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for humans (11). Noroviruses can be divided into at least five 
genogroups, designated GI–GV, based on amino acid identity 
in the major structural protein (VP1) (12). The strains that 
infect humans (referred to collectively as “human noroviruses”) 
are found in GI, GII, and GIV, whereas the strains infect-
ing cows and mice are found in GIII and GV, respectively 
(Figure 1). Although interspecies transmission of noroviruses 
has not been documented, strains that infect pigs are found 
in GII (13), and a GIV norovirus was discovered recently 
as a cause of diarrhea in dogs (14), suggesting the potential 
for zoonotic transmission. On the basis of >85% sequence 
similarity in the complete VP1 genome, noroviruses can be 
classified further into genotypes, with at least eight genotypes 
belonging to GI and 21 genotypes belonging to GII (12,13; 
CDC, unpublished data, 2011). Since 2001, GII.4 viruses 
have been associated with the majority of viral gastroenteritis 
outbreaks worldwide (15). Recent studies have demonstrated 
that these viruses evolve over time through serial changes in 
the VP1 sequence, which allow evasion of immunity in the 
human population (15,16).
Clinical Features
Noroviruses cause acute gastroenteritis in persons of all 
ages. The illness typically begins after an incubation period of 
12–48 hours and is characterized by acute onset, nonbloody 
diarrhea, vomiting, nausea, and abdominal cramps. Some per-
sons might experience only vomiting or diarrhea. Low-grade 
fever and body aches also might be associated with infection, 
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FIGURE 1. Classification of noroviruses into 5 genogroups (GI–V) and 35 genotypes based on sequence diversity in the complete capsid protein 
VP1 (human strains cluster within GI, GII, and GIV)
Sources: Data from Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006;346:312–23; 
Wang QH, Han MG, Cheetham S, Souza M, Funk JA, Saif LJ. Porcine noroviruses related to human noroviruses. Emerg Infect Dis 2005;11:1874–81; CDC, unpublished 
data, 2011; graphic developed by Everardo Vega, PhD, CDC.
* The scale bar of 0.1 reflects the number of amino acid substitutions per site.
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illness, although there is no biologic association with influenza. 
Although symptoms might be severe, they typically resolve 
without treatment after 1–3 days in otherwise healthy persons. 
However, more prolonged courses of illness lasting 4–6 days can 
occur, particularly among young children, elderly persons, and 
hospitalized patients (17,18). Approximately 10% of persons 
with norovirus gastroenteritis seek medical attention, which 
might include hospitalization and treatment for dehydration 
with oral or intravenous fluid therapy (7,19,20). Norovirus-
associated deaths have been reported among elderly persons and 
in the context of outbreaks in long-term–care facilities (21,22). 
Necrotizing enterocolitis in neonates, chronic diarrhea in 
immunosuppressed patients, and postinfectious irritable bowel 
syndrome also have been reported in association with norovirus 
infection (23–25); however, more data from analytic studies are 
needed to confirm a causal link with these conditions.
Norovirus is shed primarily in the stool but also can be 
found in the vomitus of infected persons, although it is unclear 
if detection of virus alone indicates a risk for transmission. 
The virus can be detected in stool for an average of 4 weeks 
following infection, although peak viral shedding occurs 2–5 
days after infection, with a viral load of approximately 100 
billion viral copies per gram of feces (26). However, given 
the lack of a cell culture system or small animal model for 
human norovirus, whether these viruses represent infectious 
virus is unknown, and therefore the time after illness at which 
an infected person is no longer contagious also is unknown. 
Furthermore, up to 30% of norovirus infections are asymp-
tomatic, and asymptomatic persons can shed virus, albeit at 
lower titers than symptomatic persons (26–28). The role of 
asymptomatic infection in transmission and outbreaks of 
norovirus remains unclear.
Immunity
Protective immunity to norovirus is complex and incom-
pletely understood. In human challenge studies, infected vol-
unteers were susceptible to reinfection with the same strain as 
well as to infection with heterologous strains (29–32). In addi-
tion, those with preexisting antibodies were not protected from 
infection unless repeated exposure to the same strain occurred 
within a short period. Two of these studies demonstrated that 
homologous antibody protection might last anywhere from 8 
weeks to 6 months (30,31). However, the infectious dose of 
virus given to volunteers in these challenge studies was several-
fold greater than the dose of virus capable of causing human 
illness, and thus immunity to a lower natural challenge dose 
might be greater and more cross-protective.
Because preexisting antibodies among challenged volunteers 
did not necessarily convey immunity, and some persons seemed 
to remain uninfected despite significant exposure, both innate 
host factors and acquired immunity have been hypothesized to 
contribute to the susceptibility to infection (31). Histo-blood 
group antigens (HBGAs), including H type, ABO blood group, 
and Lewis antigens have been proposed as candidate recep-
tors for norovirus. Expression of HBGAs is associated with 
strain-specific susceptibility to norovirus infection (17,33–38). 
Resistance to norovirus infections has been associated with 
mutations in the 1,2-fucosyltransferase (FUT2) gene leading 
to a lack of expression of HBGAs on the surface of intestinal 
cells (33–35,39). Thus, persons who have the normal FUT2 
gene and who express these antigens are termed “secretors” 
whereas mutations in the FUT2 gene leading to the absence 
of HBGA expression result in “nonsecretor” persons who are 
less susceptible to infection. However, secretor status does not 
completely explain the differences seen among infected and 
uninfected persons for all strains of norovirus. Thus, addi-
tional mechanisms of immunity are likely involved, and this 
remains an ongoing field of research. In addition, evidence 
suggests that new GII.4 variants evolve to escape the build-
up of acquired immunity and innate resistance in the human 
population (16,40).
Transmission
Norovirus is extremely contagious, with an estimated infec-
tious dose as low as 18 viral particles (41), suggesting that 
approximately 5 billion infectious doses might be contained 
in each gram of feces during peak shedding. Humans are the 
only known reservoir for human norovirus infections, and 
transmission occurs by three general routes: person-to-person, 
foodborne, and waterborne. Person-to-person transmission 
might occur directly through the fecal-oral route, by ingestion 
of aerosolized vomitus, or by indirect exposure via fomites or 
contaminated environmental surfaces. Foodborne transmission 
typically occurs by contamination from infected food handlers 
during preparation and service but might also occur further 
upstream in the food distribution system through contamina-
tion with human waste, which has been demonstrated most 
notably by outbreaks involving raspberries and oysters as 
vehicles (42–46). A recent outbreak involving consumption of 
delicatessen meat also demonstrated the potential for norovirus 
contamination during processing (47). Finally, recreational 
and drinking water can serve as vehicles of norovirus transmis-
sion and result in large community outbreaks (48,49). These 
outbreaks often involve well water that becomes contaminated 
from septic tank leakage or sewage (50) or from breakdowns 
in chlorination of municipal systems (51).
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Sporadic Disease
As diagnostic methods have improved and become more 
widely available, the role of noroviruses as the leading cause 
of sporadic gastroenteritis in all age groups has become clear. 
Approximately 21 million illnesses caused by norovirus are 
estimated to occur each year in the United States, approxi-
mately one quarter of which can be attributed to foodborne 
transmission (52). A recent systematic review of 31 community, 
outpatient, and hospital-based studies in both developed and 
developing countries estimated that noroviruses accounted for 
10%–15% of severe gastroenteritis cases in children aged <5 
years and for 9%–15% of mild and moderate diarrhea cases 
among persons of all ages (53). Although laboratory-based data 
on endemic norovirus disease in the United States are sparse, 
recent studies suggest that norovirus is the leading cause of acute 
gastroenteritis in the community and among persons seeking 
care in outpatient clinics or emergency departments across all 
age groups (54,55; CDC, unpublished data, 2011).
Serosurveys have demonstrated that norovirus infections are 
prevalent throughout the world, with initial exposure typically 
occurring early in life (5). In population-based studies from 
Australia, England, Hong Kong, and the Netherlands, norovi-
rus infection has accounted for 9%–24% of gastroenteritis cases 
(19,20,56–58). In these studies, infection was more frequent in 
certain age groups (e.g., children aged <5 years and adults aged 
>65 years). In studies that have used sensitive molecular assays, 
a relatively high prevalence of norovirus-positive samples in 
asymptomatic persons has been detected, ranging from 5% in 
the Netherlands to 16% in England (20,56). This background 
rate of asymptomatic infection, coupled with innate resistance 
attributable to secretor status and acquired immunity, helps 
explain why attack rates rarely exceed 50% in outbreaks.
Outbreaks
Noroviruses are the predominant cause of gastroenteritis out-
breaks worldwide. Data from the United States and European 
countries have demonstrated that norovirus is responsible for 
approximately 50% of all reported gastroenteritis outbreaks 
(range: 36%–59%) (5). Outbreaks occur throughout the year 
although there is a seasonal pattern of increased activity during 
the winter months. In addition, periodic increases in norovirus 
outbreaks tend to occur in association with the emergence of 
new GII.4 strains that evade population immunity (Table) 
(40,59). These emergent GII.4 strains rapidly replace existing 
strains predominating in circulation and can sometimes cause 
seasons with unusually high norovirus activity, as in 2002–2003 
and 2006–2007. Because the virus can be transmitted by food, 
water, and contaminated environmental surfaces as well as 
directly from person to person, and because there is no long 
lasting immunity to norovirus, outbreaks can occur in a variety 
of institutional settings (e.g., nursing homes, hospitals, and 
schools) and affect people of all ages. Whereas prior national 
estimates of outbreak attribution by mode of transmission were 
likely biased toward foodborne disease (60,61), more recent 
data from individual states indicate that the majority of norovi-
rus outbreaks primarily involve person-to-person transmission 
(62,63). Multiple routes of transmission can occur within an 
outbreak; for example, point-source outbreaks from a food 
exposure often result in secondary person-to-person spread 
within an institution or community. Of the 660 norovirus 
outbreaks laboratory confirmed by CDC during 1994–2006 
that indicated the setting, 234 (35.4%) were from long-term–
care facilities (e.g., nursing homes); 205 (31.1%) were from 
restaurants, parties, and events; 135 (20.5%) were from vaca-
tion settings (including cruise ships); and 86 (13.0%) were 
from schools and communities (59). Although GII.4 variants 
predominate overall, the role of GI and other GII genotypes 
appears to be greater in settings that involve foodborne or 
waterborne transmission (Figure 2).
Long-Term Care and Other Health-Care Facilities
Health-care facilities including nursing homes and hospitals 
are the most commonly reported settings of norovirus out-
breaks in the United States and other industrialized countries 
(59,60,63–65). Virus can be introduced from the community 
into health-care facilities by staff, visitors, and patients who 
might either be incubating or infected with norovirus upon 
admission or by contaminated food products. Outbreaks in 
these settings can be prolonged, sometimes lasting months 
(66). Illness can be more severe in hospitalized patients than 
for otherwise healthy persons (18), and associated deaths 
have been reported (21,22). Strict control measures (includ-
ing isolation or cohorting of symptomatic patients, exclusion 
of affected staff, and restricting new admissions into affected 
units) are disruptive and costly but might be required to curtail 
outbreaks (9,67,68).
Restaurants and Catered Events
Norovirus is now recognized as the leading cause of food-
borne disease outbreaks in the United States. Norovirus 
accounted for 822 (35%) of the 2,367 foodborne disease 
outbreaks reported to CDC during 2006–2007 (Figure 3) and 
half of the 1,641 foodborne disease outbreaks with a confirmed 
or suspected etiology (69,70). Food can become contaminated 
with norovirus at any point during production, processing, 
distribution, and preparation. Thus, a variety of products 
have been implicated in outbreak investigations; foods eaten 
raw (e.g., leafy vegetables, fruits, and shellfish) are identified 
most commonly (69,70). Handling of ready-to-eat foods by 
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infected food employees is commonly identified as a contribut-
ing factor in outbreaks of foodborne norovirus associated with 
food-service establishments (71,72). Norovirus outbreaks also 
have resulted from fecal contamination of certain food prod-
ucts at the source. For example, oysters harvested from fecally 
contaminated growing waters and raspberries irrigated with 
sewage-contaminated water have been implicated in outbreaks 
(44,73). Because gross sewage contamination will contain a 
collection of viruses circulating in the community, multiple 
norovirus genotypes often are detected in such outbreaks. 
Contamination with norovirus also can occur during process-
ing, as demonstrated by a recent outbreak involving delicates-
sen meat (47). Only a small dose of virus is needed to cause 
infection, and thus infected food handlers can contaminate 
large quantities of product. For example, approximately 500 
cases of gastroenteritis were reported during a 2006 outbreak 
caused by a foodhandler who vomited at work (74). Drinking 
water or ice also might become contaminated with norovirus 
and result in outbreaks in food-service settings. Secondary 
person-to-person transmission is common following point-
source food or water exposures.
Schools and Other Institutional Settings
Norovirus outbreaks occur in a range of other institutional 
settings including schools, child care centers, colleges, prisons, 
and military encampments. Outbreaks of gastroenteritis in 
child care centers also are caused by other pathogens, includ-
ing rotavirus, sapovirus, and astrovirus, as a result of a lack of 
immunity to these viruses in young populations (75). Outbreaks 
have been reported recently from multiple universities in differ-
ent states and have led to campus closures (76). An interven-
tion study in elementary schools demonstrated that improved 
hand hygiene and surface disinfection can lead to lower rates of 
TABLE. Emergent norovirus variants of genogroup II type 4 (GII.4), including those associated with epidemic winter seasons of increased 
outbreaks — United States
Emergent GII.4 variant Yrs of circulation Epidemic Season Other name(s)
95/96-US 1995–2002 1995–1996 Grimsby
Farmington Hills 2002–2005 2002–2003 2002 variant
Hunter 2003–2006 None 2004 variant
Yerseke 2006–2008 2006–2007 Laurens, Nijmegen, 2006a variant
Den Haag 2006–present 2006–2007 Minerva, 2006b variant
New Orleans 2009–present None*
Sources: Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006; 
J Clin Microbiol 2010;48:168–77; CDC, unpublished data, 2010.
* On the basis of data available as of September 2010, the New Orleans GII.4 variant has not been associated with an increased number of norovirus outbreaks in the 
United States. 
FIGURE 2. Number* of norovirus outbreaks laboratory-confirmed by 
CDC, by setting and genotype — United States, 1994–2006
Source: Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epidemiology of 
genogroup II-genotype 4 noroviruses in the United States between 1994 and 
2006. J Clin Microbiol 2010;48:168–77.
* N = 660.































FIGURE 3. Number* of foodborne disease outbreaks reported to 
CDC, by etiology — United States, 2006–2007
Sources: CDC. Surveillance for foodborne disease outbreaks —United States, 
2006. MMWR 2009;58:609–5; CDC. Surveillance for foodborne disease out-
breaks—United States, 2007. MMWR 2010;59:973–9.
* No. = 2,367.
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absenteeism caused by nonspecific gastroenteritis and reduced 
surface contamination with norovirus (77). Norovirus was 
also the most common cause of gastroenteritis in U.S. marines 
during Operation Iraqi Freedom (78) and a common cause of 
outbreaks among deployed British troops (79).
Cruise Ships and Other Transportation Settings
Passengers and crew aboard cruise ships are affected frequently 
by norovirus outbreaks (80). Virus generally is introduced on 
board by passengers or crew infected before embarkation but 
might also result from food items contaminated before loading 
or persistently contaminated environmental surfaces from pre-
vious cruises. Virus also might be acquired when ships dock in 
countries where sanitation might be inadequate, either through 
contaminated food or water or passengers becoming infected 
while docked. Repeated outbreaks can occur in subsequent sail-
ings as a result of environmental persistence or infected crew, 
particularly if control measures have not been implemented 
consistently and thoroughly. Genotyping of outbreak strains 
from repeated outbreaks has demonstrated that this can occur 
through the introduction of new virus or recrudescence of virus 
from one sailing to the next (81,82). CDC’s Vessel Sanitation 
Program assists the cruise ship industry in preventing and con-
troling the introduction and transmission of gastrointestinal 
illness by inspecting cruise ships, monitoring gastrointestinal 
illnesses, and responding to outbreaks (http://www.cdc.gov/
nceh/vsp). Outbreaks also have been reported in association 
with bus tours and air travel, in which environmental con-
tamination and proximity to ill passengers facilitated norovirus 
transmission (83,84).
Diagnostic Methods
The majority of clinical virology laboratories perform real-
time reverse transcription-polymerase chain reaction (RT-PCR) 
assays (specifically, TaqMan-based real-time assays) for noro-
virus detection. These assays have not been cleared by FDA 
although commercial kits are available in the United States. 
Positive samples can be typed subsequently by DNA sequencing 
of conventional RT-PCR products. FDA has recently cleared 
the RIDASCREEN Norovirus 3rd Generation (r-Biopharm, 
AG, Darmstadt, Germany) enzyme immunoassay (EIA) for 
preliminary identification of norovirus as the cause of an AGE 
outbreak. However, negative EIA results should be confirmed 
by RT-PCR reference methods.
Real-Time RT-PCR Assays
The ORF1-ORF2 junction region is the most conserved 
region of the norovirus genome, with a high level of nucleotide 
sequence identity across strains within a genogroup (85,86). 
This feature makes this region ideal for designing broadly reac-
tive primers and probes for TaqMan-based real-time RT-PCR 
(RT-qPCR) assays (Figure 4). The majority of published 
assays are derived from the original publication (86), which 
has been modified into one-step and duplex assays (87,88) for 
high throughput screening in clinical diagnostic laboratories. 
In addition to detecting norovirus RNA in clinical samples, 
relatively small optimizations of the primers and probes have 
resulted in sensitive assays to detect norovirus RNA in environ-
mental samples (e.g., food and water) (64,89–91). The extreme 
analytic sensitivity of RT-qPCR permits the detection of very 
low titers of virus that might be present in samples from per-
sons without disease caused by norovirus (i.e., asymptomatic 
infection) (28). For this reason, low titer results (i.e., high cycle 
threshold [CT] values) should be interpreted with caution.
Conventional RT-PCR Assays 
for Genotyping
Four different regions (designated A–D) of the genome have 
been used successfully for genotyping of noroviruses (92,93). 
However, typing based on the capsid gene (region C and region 
D) allows for better differentiation between strains (Figure 4). 
Although region C sequences have been used widely for geno-
typing strains by clinical diagnostic laboratories in the United 
States, Europe, and Japan, the resolution of this region is not 
sufficient to distinguish differences between certain GII.4 
variants, which are the predominant strains associated with 
outbreaks (59). The gold standard for genotyping norovirus 
strains is full capsid sequencing. However, for clinical samples 
with high copy numbers, amplifying partial capsid sequences 
is more practical and is only slightly less discriminatory than 
full capsid sequencing (92). For this reason, laboratories par-
ticipating in CaliciNet, CDC’s electronic norovirus outbreak 
surveillance network (see Reporting and Assistance), use region 
D genotyping.
Enzyme Immunoassays
For detection of norovirus antigen in clinical samples, rapid 
assays (e.g., EIA) offer an attractive alternative to expensive and 
technically demanding molecular detection assays. However, 
the development of a broadly reactive EIA for noroviruses 
has been challenging because of the number of antigenically 
distinct norovirus strains and the high viral load required for 
a positive signal by these assays. Commercial kits, includ-
ing IDEIA Norovirus EIA (Oxoid, Ely, United Kingdom), 
SRSV (II)-AD (Denka Seiken Co. Ltd., Tokyo, Japan), and 
RIDASCREEN include pools of cross-reactive monoclonal and 
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polyclonal antibodies (94–101). In evaluations, the sensitivity 
of these kits when compared with RT-PCR has ranged from 
36% to 80%, and specificity has ranged from 47% to 100% 
(94–101). Because of the modest performance of these com-
mercial kits, particularly their poor sensitivity, they are not 
recommended for clinical diagnosis of norovirus infection in 
sporadic cases of gastroenteritis. However, given their ease of 
use and rapid results, EIA kits with high specificity (>85%) 
and at least moderate sensitivity (>50%) might be useful for 
preliminary screening of multiple fecal samples associated with 
an outbreak of acute gastroenteritis. These kits are not widely 
available in the United States, although the RIDASCREEN 
Norovirus 3rd Generation EIA has been recently cleared by 
FDA for preliminary identification of norovirus as the cause 
of AGE outbreaks. Nonetheless, negative samples will have to 
be confirmed by a second technique such as RT-qPCR, and 
therefore EIA kits should not be regarded as a replacement for 
molecular methods during outbreak investigations.
Specimen Collection
Clinical Specimens
Whole stool specimens should be collected for laboratory 
diagnosis of norovirus and are preferred over rectal swabs because 
of the higher quantity of virus present in whole stool. Vomitus 
also may be collected and tested using molecular assays, although 
unlike for stool, the sensitivity of these assays for vomitus is 
unknown. To aid in interpretation, each specimen should be 
accompanied with dates of symptom onset and specimen col-
lection. An outbreak of acute gastroenteritis is considered to 
be laboratory-confirmed as attributable to norovirus if stool or 
vomitus specimens from two or more ill persons are positive for 
norovirus by RT-PCR, EIA, or electron microscopy (71).
Stool
Timing. Specimen collection for norovirus testing should 
begin as early as possible in an epidemiologic investigation. 
Unnecessary delays while awaiting results from testing for 
bacterial or parasitic agents could preclude establishment of 
a viral diagnosis. Ideally, whole stool specimens should be 
obtained during the acute phase of illness (i.e., within 48–72 
hours after onset) while the stools are still liquid or semisolid 
and viral excretion is at its peak. When this is not possible, 
specimens collected later in illness or after resolution (i.e., up 
to 7–10 days after onset) might still provide a diagnosis and 
an opportunity to confirm norovirus infection in a suspected 
source case-patient (e.g., a food handler with a recent history 
of diarrhea). If specimens are collected late in the illness, 
the utility of viral diagnosis and interpretation of the results 
should be discussed with laboratory personnel before tests are 
conducted (see Reporting and Assistance).
Number and quantity. Obtaining a collection of high 











85/98 bp 330/344 bp
Norovirus detection Norovirus genotyping
FIGURE 4. Genomic regions targeted by reverse transcription-polymerase chain reaction (RT-PCR) assays used for norovirus detection 
and genotyping
Abbreviations: ORF = open reading frame; RT = TaqMan real-time RT-PCR region for norovirus detection (87); C = region C for norovirus genotyping (93); D = region 
D for norovirus genotyping (92); and bp = base pairs.
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diagnostic specimens is crucial for laboratory confirmation. 
Whole stool specimens from at least five ill persons are recom-
mended. This number should be increased if specimens are 
taken after the acute phase of illness, in large or protracted 
outbreaks, or if less sensitive EIA diagnostics are employed. 
On the basis of test characteristics of commercially available 
EIAs, six specimens are required to achieve >90% sensitivity 
in outbreak diagnosis (101,102). Bulk samples (i.e., 10–50 
mL of whole stool placed in a stool cup or urine container) 
are preferred, because rectal swabs are generally insufficient 
(CDC, unpublished data, 2011).
Storage and transport. Whole stool specimens should be 
kept refrigerated at 39°F (4°C) if testing occurs within 2–3 
weeks. At this temperature, specimens can be stored without 
compromising diagnostic yield. If the specimens have to be 
transported to a laboratory for testing, they should be indi-
vidually bagged and sealed and kept on ice or frozen refriger-
ant packs in an insulated, waterproof container. If testing is 
expected to occur >3 weeks after collection or for archiving pur-
poses, stool samples should be frozen at -4°F (-20°C) or -94°F 
(-70°C). Norovirus RNA can be detected by using molecular 
assays after at least 5 years when samples are stored under these 
conditions (59). Although it was previously recommended 
to avoid freezing stool specimens because of degradation of 
viral morphology and consequent hampering of diagnosis by 
electron microscopy (8), this is no longer a concern because 
of the widespread use of molecular assays.
Vomitus
Specimens of vomitus can be collected to supplement the 
diagnostic yield from stool specimens during an investigation. 
Recommendations for collection, storage, and shipment of 
vomitus specimens are the same as those for stool specimens.
Serum
Serum specimens might be useful in unique circumstances or 
for special studies but are not recommended for routine diag-
nostics. If feasible and warranted, acute- and convalescent-phase 
serum specimens may be obtained to test for a greater-than-
fourfold rise in IgG titer to noroviruses. Acute-phase specimens 
should be obtained during the first 5 days after symptom onset, 
and the convalescent-phase specimens should be collected during 
the third to fourth week after resolution of symptoms. Because 
these assays are not available commercially, CDC may be con-
tacted for further guidance on collection, processing, and storage 
of serum specimens (see Reporting and Assistance).
Environmental Specimens
Because human noroviruses cannot be grown in cell culture, 
current detection methods (e.g., RT-qPCR) allow detection of 
norovirus RNA in water, food, and environmental specimens; 
however, validated methods are available only for water (at 
CDC) and shellfish (at FDA’s Gulf Coast Seafood Laboratory). 
If a food or a water source is strongly suspected as the source of 
an outbreak, a sample should be obtained as early as possible 
with respect to the time of exposure and preferably stored frozen 
at -4°F (-20°C), and CDC or FDA should be contacted for fur-
ther guidance on testing. Detection of norovirus in food requires 
appropriate elution and concentration techniques which need 
to be adapted for each food vehicle. At present, these methods 
are not available routinely, except for shellfish. Water can be 
tested for noroviruses after concentration of large volumes (e.g., 
up to 100 L of water) through specially designed filters (103). 
Environmental surface swabs have also been demonstrated to 
detect norovirus RNA in specific outbreak settings (104,105). 
Depending on the specific situation, epidemiologic findings, 
and expected level of contamination, collection of environmen-
tal specimens might be warranted and should be pursued in 
consultation with CDC. (See Reporting and Assistance).
Prevention and Control
Hand Hygiene
Appropriate hand hygiene is likely the single most important 
method to prevent norovirus infection and control trans-
mission. Reducing any norovirus present on hands is best 
accomplished by thorough handwashing with running water 
and plain or antiseptic soap. Washing with plain soap and 
water reduces the number of microbes on hands via mechani-
cal removal of loosely adherent microorganisms (106). The 
efficacy of alcohol-based and other hand sanitizers against 
norovirus remains controversial with mixed evidence depend-
ing on the product formulation and evaluation methodology. 
In finger pad studies, soap and water used for 20 seconds have 
been demonstrated to reduce norovirus by 0.7–1.2 log10 by 
RT-PCR assay, whereas alcohol-based hand sanitizers did not 
demonstrate any appreciable reduction of viral RNA (107). 
However, such studies cannot determine whether the residual 
virus remains viable given the inability to cultivate human 
norovirus in vitro.
Studies using cultivable surrogate viruses such as murine 
norovirus (MNV) or feline calicivirus (FCV) have demon-
strated that ethanol has superior efficacy against FCV com-
pared with other alcohols (e.g., propanol-1 and propanol-2), 
and formulations containing 70% ethanol were able to reduce 
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infectious MNV by 2.5 log10 after 30 seconds (108–110). The 
sensitivity of FCV to low pH and the relatively high susceptibil-
ity of MNV to alcohols suggest that sanitizers that are effective 
against both surrogate viruses might be more likely to be effec-
tive against human norovirus, than those effective against only 
one of the surrogates (111). In addition, reduction of viral RNA 
(as opposed to reduced infectivity of cultivable surrogates) does 
not appear to be a reliable means of estimating the effectiveness 
of hand sanitizers against human norovirus (111).
Overall, studies suggest that proper hand washing with soap 
and running water for at least 20 seconds is the most effec-
tive way to reduce norovirus contamination on the hands, 
whereas hand sanitizers might serve as an effective adjunct in 
between proper handwashings but should not be considered 
a substitute for soap and water handwashing (106–111). As 
an additional preventive strategy, no bare-hand contact with 
ready-to-eat foods (foods edible without washing, cooking, or 
additional preparation to achieve food safety) is recommended 
(112; FDA, unpublished data, 2011).
Exclusion and Isolation
Considering the highly infectious nature of norovirus, 
exclusion and isolation of infected persons are often the most 
practical means of interrupting transmission of virus and lim-
iting contamination of the environment. This is particularly 
important in settings where people reside or congregate such as 
long-term–care facilities, acute-care hospitals, cruise ships, and 
college dormitories. Empiric evidence for the effectiveness of 
exclusion and isolation strategies is limited (113); rather, strate-
gies are based on infection-control principles. The principle 
underpinning isolation is to minimize contact with persons 
during the most infectious periods of their illness. This includes 
the acute phase of illness, a period following recovery while 
the person is still shedding virus at high levels (usually 24–72 
hours), and, in some situations in health-care facilities, exclu-
sion of exposed and potentially incubating persons. Isolation 
of both exposed and unexposed well persons might be useful 
during outbreaks in long-term–care facilities to help break the 
cycle of transmission and prevent additional cases. In health-
care facilities, ill patients may be cohorted together in a unit 
or part thereof, with dedicated nursing staff providing care for 
infected persons (9). Analogously, passengers with gastroenteri-
tis on cruise ships may be asked to remain isolated voluntarily 
in their cabins during their illness and for a period of 24–48 
hours after their symptoms have resolved. Ill patients generally 
should not be transferred to unaffected units in the facility or 
to other facilities, except in the case of medical necessity and 
after consultation with infection-control staff. To minimize the 
risk of spread from incubating or asymptomatically infected 
patients and staff in health-care facilities, such persons should 
not be transferred to or work on (respectively) unaffected 
areas, typically for 48 hours after exposure. Ill staff members 
in health-care facilities and food handlers should be excluded 
during their illness and for 48–72 hours following resolution 
of symptoms. Asymptommatic food-service workers who have 
tested positive for norovirus, which might occur during an 
outbreak investigation, also should be excluded or restricted 
per the FDA Food Code (10). Regulatory authority approval 
might be required for excluded food-service workers to return 
to work (10), although requiring negative stool results prior 
to returning to work is not recommended. Sick pay and sick 
leave policies that do not penalize ill workers might help to 
facilitate such staff exclusion. Nonessential personnel, includ-
ing visitors, may be screened for symptoms and excluded or, at 
the minimum, should be cautioned about the risks and made 
aware of the heightened importance of hand hygiene through 
washing with soap and water. In certain situations, units in a 
health-care facility may be closed to new admissions to prevent 
the introduction of new susceptible patients (113).
Environmental Disinfection
The use of chemical disinfectants is one of the key approaches 
to interrupt norovirus spread from contaminated environ-
mental surfaces. Particular attention should be given to the 
likely areas of greatest environmental contamination such 
as bathrooms and high-touch surfaces (e.g., door knobs and 
hand rails). Sodium hypochlorite (chlorine bleach) has been 
widely recommended to disinfect human norovirus from sur-
faces, and its efficacy has been well documented (114–117). 
Environmental surfaces potentially contaminated with 
norovirus should be disinfected using a sodium hypochlorite 
solution or other commercial product registered with EPA as 
effective against norovirus. A list of EPA-approved products 
is available at http://www.epa.gov/oppad001/list_g_norovirus.
pdf. Products containing phenolic compounds (including 
triclosan and quarternary ammonium compounds) are less 
effective against nonenveloped viruses such as human norovirus 
(114,118–120). Furthermore, this list should be interpreted 
with caution because the efficacy of these products is deter-
mined by using the surrogate FCV, which exhibits different 
physiochemical properties than human norovirus and therefore 
might not reflect a similar disinfection efficacy profile (121). In 
addition, several recent reports have demonstrated that FCV is 
not the most resistant surrogate virus to predict inactivation of 
human norovirus (111,122,123). Therefore, the use of multiple 
surrogate viruses rather than a single surrogate has been sug-
gested to assess the efficacy of disinfectants (111).
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Because of this uncertainty, whenever possible, chlorine 
bleach solution should be applied to hard, nonporous, environ-
mental surfaces at a concentration of 1,000–5,000 ppm (5–25 
tablespoons household bleach [5.25%] per gallon of water). 
Given the potential for evaporative dilution, bleach solutions 
should be freshly prepared for use within 24 hours, or the 
target concentration should be doubled (e.g., 2,000–10,000 
ppm) for storage and used within 30 days. Although the upper 
end of this range has been recommended previously when 
soiling is present (124), few data are available to support the 
effectiveness of sodium hypochlorite on fecally soiled surfaces 
(125). For example, 5,000 ppm of sodium hypochlorite was 
not able to completely eliminate norovirus dried in 20% fecal 
stool suspension on surfaces (126). A recent study indicated 
that longer exposure times (approximately 4 minutes) of 
5,000 ppm sodium hypochlorite on fecally soiled surfaces 
were needed to inactivate both human norovirus surrogates 
(MNV and FCV) by 4 log10 (122), which has been proposed 
as a satisfactory reduction level for norovirus contamination 
(127). In conclusion, initial cleaning of contaminated surfaces 
to remove organic loads such as fecal material should be per-
formed before sodium hypochlorite disinfection.
In health-care settings, cleaning products and disinfectants 
used should be EPA-registered and have label claims for use 
in health-care settings; personnel performing environmental 
services should adhere to the manufacturer’s instructions for 
dilution, application, and contact time. Heat disinfection (i.e., 
pasteurization to 140°F [60°C]) has been suggested and used 
successfully under laboratory conditions, for items that cannot 
be subjected to chemical disinfectants such as chlorine bleach 
(128–131). Other disinfection approaches such as ozone, 
hydrogen peroxide, or coating surfaces with antimicrobial 
materials (e.g., titanium dioxide [TiO2] film) also have been 
proposed for routine environmental control of noroviruses 
(132–134).
Reporting and Assistance
Individual cases of norovirus are not nationally notifiable; 
however, all outbreaks of acute gastroenteritis should be 
reported to the appropriate local or state health departments, 
in accordance with local regulations. Additional outbreak assis-
tance, including coordination of multistate outbreak investiga-
tions, epidemiologic consultation, and laboratory support can 
be provided by the CDC Norovirus Program located within the 
Division of Viral Diseases, National Center for Immunization 
and Respiratory Diseases. After telephone consultation with 
the National Calicivirus Laboratory (404-639-1923), state or 
local public health laboratories can ship outbreak specimens 
to CDC at National Calicivirus Laboratory, Dash Unit 75, 
CDC, 1600 Clifton Road, N.E., Atlanta, GA 30333.
National Outbreak Reporting System
In response to a position statement by the Council of State 
and Territorial Epidemiologists, CDC developed the National 
Outbreak Reporting System (NORS) as an integrated national 
surveillance system for enteric disease outbreaks that combined 
and expanded on the longstanding national surveillance sys-
tems for foodborne and waterborne outbreaks. Launched in 
February 2009, NORS provides a framework through which 
all outbreaks of enteric disease, regardless of transmission mode, 
may be reported from state and local health departments to 
CDC. This web-based platform includes modules for outbreaks 
attributable to foodborne, waterborne, and person-to-person 
outbreaks, thereby providing comprehensive national surveil-
lance for all gastroenteritis outbreaks, including those caused by 
norovirus. Data collected through NORS will help determine 
the burden and trends of epidemic norovirus and attribution to 
settings, transmission routes, and food vehicles. Such informa-
tion is critical to develop appropriate prevention and control 
strategies that target points of intervention most likely to yield 
the greatest impact. States are encouraged to contribute to 
this national surveillance effort by reporting all suspected and 
confirmed norovirus outbreaks through NORS.
CaliciNet
Genotyping of norovirus strains has been demonstrated to 
be useful in confirming or identifying links between clusters 
of norovirus illness, and direct sequencing of RT-PCR prod-
ucts has become the method of choice. To increase the value 
of national norovirus surveillance, CDC has developed and 
implemented an electronic norovirus outbreak surveillance 
network (CaliciNet) with state and local public health and 
food regulatory agency laboratories. CaliciNet is intended 
to link norovirus outbreaks to aid in identifying common 
(e.g., food) vehicles, identify trends, and identify emerging 
norovirus strains. Using standardized genotyping methods, 
CaliciNet-certified laboratories upload norovirus sequences 
and conduct rapid comparison with sequences already in 
the database. CaliciNet was implemented in March 2009, 
and as of January 2011, a total of 21 states were certified for 
participation. With continued development and expansion of 
the network, CaliciNet might help elucidate the role of food 
contamination throughout the continuum from production 
to preparation and the evolution of specific norovirus strains 
in causing outbreaks, which ultimately can help better target 
interventions.
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